The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully

Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule 

Cancer imaging and identification of predictive biomarkers are the best performed tasks reported in studies presented at ESMO Congress 2023

Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe

Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma 

Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo 

Results from studies presented at the ESMO Congress 2023 (Madrid, 20–24 October) outline different strategies involving indirect immune modulation and direct enhanced tumour cytotoxicity to improve on chemotherapy as the current standard of second-line care after ICI progression

Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery